Bright Minds Biosciences Inc.
DRUG
CNSX
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 22.30% | -9.19% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | 200.43% | -- | |||
| Total Operating Expenses | 91.31% | -3.10% | |||
| Operating Income | -91.31% | 3.10% | |||
| Income Before Tax | 21.72% | -84.33% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 21.72% | -84.33% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 21.72% | -84.33% | |||
| EBIT | -91.31% | 3.10% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 23.33% | -83.12% | |||
| Normalized Basic EPS | 23.33% | -83.18% | |||
| EPS Diluted | 22.73% | -82.81% | |||
| Normalized Diluted EPS | 23.33% | -83.18% | |||
| Average Basic Shares Outstanding | 2.11% | 0.65% | |||
| Average Diluted Shares Outstanding | 2.11% | 0.65% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||